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ABSTRACT
OBJECTIVE: To assess the prevalence of the use of medicines and other products for therapeutic 
purposes in the Brazilian pediatric population and test whether demographic, socioeconomic 
and health factors are associated with use.
METHODS: A cross-sectional population-based study (National Survey on Access, Use and 
Promotion of Rational Use of Medicines – PNAUM), including 7,528 children aged 12 or younger, 
living in urban areas in Brazil. Medicine use to treat chronic or acute diseases was reported by 
the primary caregiver present at the household interview. Associations between independent 
variables and medicine use were investigated by Poisson regression.
RESULTS: The overall prevalence of medicine use was 30.7% (95%CI 28.3–33.1). The prevalence of 
medicine use for chronic diseases was 5.6% (95%CI 4.7–6.7) and for acute conditions, 27.1% (95%CI 
24.8–29.4). The factors significantly associated with overall use were five years old or under, living 
in the Northeast region, having health insurance and using health services in the last 12 months 
(emergency visits and hospitalizations). The following were associated with drug use for chronic 
diseases: age ≥ 2 years, Southeast and South regions, and use of health services. For drug use in 
treating acute conditions, the following associated factors were identified: ≤ 5 years, North, Northeast 
or Midwest regions, health insurance, and one or more emergency visits. The most commonly used 
drugs among children under two years of age were paracetamol, ascorbic acid, and dipyrone; for 
children aged two years or over they were dipyrone, paracetamol, and amoxicillin.
CONCLUSIONS: The use of medicine by children is considerable, especially in treating acute 
medical conditions. Children using drugs for chronic diseases have a different demographic profile 
from those using drugs for acute conditions in relation to gender, age, and geographic region.
DESCRIPTORS: Child. Child, Preschool. Drug Utilization. Socioeconomic Factors. Health Surveys. 
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INTRODUCTION
Drug use in children differs from drug use in adults for various reasons, especially lower 
prevalence of chronic diseases and higher degree of uncertainty in prescription and use. 
The uncertainty regarding the effectiveness and safety of medicines available for this 
population subgroup contributes to children being considered a risk group. Most drugs used 
in children have only been tested in adults, and it is observed a lack of products available 
in age-appropriate pharmaceutical formulations and dosage forms, as well as of studies on 
long-term effectiveness and safety6.
In 2007, the World Health Organization launched the campaign “Make Medicines Child 
Size” and published the First List of Essential Medicines for Children, aiming to raise 
awareness and speed up action to improve the availability of and access to medicines 
that are safe and suitable for children. Regulatory measures and measures to foster the 
research, development, and registration of drugs for use in children have occurred in 
the United States (US) and the European Union. Organizations like UNITAID, Drugs for 
Neglected Diseases initiative (DNDi) and Medicines Patent Pool (MPP) have stimulated 
the development and provision of appropriate medicines for children, such as for HIV 
and neglected diseases13.
These initiatives highlight the need to develop better medicines for children, an area that 
is considered neglected by various international organizations. In this regard, information 
on the prevalence of drug use, user characteristics and medicines used by the pediatric 
population are important to evaluate the appropriateness of use and estimate therapeutic 
needs, to improve pediatric therapeutics3,17.
In this context, community-based epidemiological studies offer a unique opportunity 
to profile drug use. Such studies provide more accurate estimates and enable a greater 
generalization of findings compared to studies based on samples of health service users, 
disease-specific carriers, or on data collected for other purposes (prescriptions or dispensing 
data, for example)1.
In Brazil, no study with a representative sample of the country has been carried out, and 
population-based studies have been limited to samples of children living in municipalities 
in the South, Southeast, and Northeast Regions8,19,20,23. In these studies, prevalence of 
use of at least one medicine ranged around 50.0%, with variations according to the age 
group investigated.
The aim of this study was to estimate the prevalence of the use of drugs and other products 
for therapeutic purposes in the Brazilian pediatric population and test whether demographic, 
socioeconomic and health factors are associated with use.
METHODS
The data in this analysis are part of the National Survey on Access, Use and Promotion 
of Rational Use of Medicines (PNAUM), a cross-sectional population-based study. 
The study’s population was composed of individuals aged 12 or younger living in 
permanent private households in urban areas within the five Brazilian regions. Specific 
questionnaires were answered by the primary caregiver present at the residence at 
the time of the interview.
The sampling plan was complex and resulted in a representative sample of the Brazilian 
population residing in urban areas. The composition of the sample, sampling procedures 
and other methodological details of PNAUM are available in a previous publication18.
The use of drugs to treat chronic diseases was investigated for respiratory diseases, 
diabetes, and other health conditions lasting six months or longer. Specific questions 
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were formulated for chronic respiratory diseases and diabetes, since they are diseases 
with high prevalence among children or that require complex administration of 
medicines. Caregivers were asked whether the child had a medical diagnosis and 
indication for the use any kind of drug to treat the related chronic disease and whether 
such medicines was being used.
For acute conditions (occasional health problems), specific questions were asked (“In the 
past 15 days, did <<child’s name>> use any medicine for infection/sleeping or nervous 
symptoms/stomach or bowel problems/fever/pain/cold or flu/diarrhea and vomiting?”). 
The use of vitamins was also investigated with the question “In the last 15 days, did <<child’s 
name>> use any vitamin, mineral supplement, appetite stimulant or tonic?” At the end of 
this set of questions, the respondent was asked about the use of drugs in the previous 15 days 
for any other health reasons. They were asked to provide, whenever possible, the packages 
or prescriptions of used medicines.
Outcomes to investigate prevalence in the pediatric sample were defined as: 
1) prevalence of overall drug use (use of at least one drug, regardless of reason for use); 
2) prevalence of drug use for chronic diseases (use of at least one drug to treat chronic 
disease); 3) prevalence of drug use for acute diseases or conditions (use of at least one 
drug to treat acute disease or health event). The outcome variables were categorized 
as yes/no. Prevalence calculation included herbal medicines and other products for 
therapeutic purposes mentioned by respondents (dietary supplements, foods, plants, 
and homeopathic products).
The following demographic and socioeconomic characteristics were analyzed: gender 
( female; male), age (< 2 years; 2-5 years; 6-12 years), skin color (white; non-white), 
economic classification according to the Economic Classification Criterion developed 
by the Brazilian Association of Survey Companies (CCEB 2013/ABEP) (A/B, C, D/E)a 
and Brazilian region (North, Northeast, Southeast, South, Midwest). Medical variables 
were: health insurance (yes; no); number of emergency visits in the last 12 months 
(none; one; two or more); and number of hospitalizations in the last 12 months (none; 
one; two or more).
The age group investigated was based on the classification adopted by the Food and Drug 
Administration (FDA) for clinical investigation of medicines for pediatricsb, more commonly 
used in previous studies, to facilitate comparison of results. We chose to analyze children 
aged 12 and under, as this is an age group in which drug use it still determined and directly 
supervised by parents or caregivers.
Based on the names of the products or medicines mentioned by respondents, the drugs were 
identified in The Brazillian Health Regulatory Agency (ANVISA) drug lists and classified 
according to the pharmacological agent(s) present in their composition. Drugs used in 
combination (containing two or more pharmacological agents in their composition) were 
considered just once.
In calculating prevalence of drug use, the total number of children in the weighted sample 
was used as the denominator, with 95% confidence intervals (95%CI). Likewise, estimates of 
prevalence of drug use with frequency equal to or above 0.5% also used as the denominator 
the total number of children present in the weighted sample, stratified by age (< 2 years; 
2-5 years; 6-12 years). For the description of the most commonly used drugs, the percentage 
denominator was the total amount of drugs in each age group.
Pearson’s Chi-squared test was used for the bivariate comparison of percentages, considering 
p < 0.05 values as significant.
Associations between independent variables and outcomes were estimated by prevalence 
ratio (PR), with 95%CI. Poisson regression models were developed to estimate crude 
PR and PR adjusted for independent variables. In the first stage, independent variables 
a Associação Brasileira de 
Empresas de Pesquisa. Critério 
de Classificação Econômica 
Brasil 2013. São Paulo (SP): 
ABEP; 2013 [cited 2016 Feb 29]. 
Available from: http://www.abep.
org/criterio-brasil
b Food and Drug Administration. 
Guidance for industry:E11 
clinical investigation of 
medicinal products in the 
pediatric population. Rockville 
(MD); 2000 [cited 2016 Feb 
29]. Available from: http://
www.fda.gov/downloads/
Drugs/GuidanceCompliance 
RegulatoryInformation/
Guidances/UCM073143.pdf
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were analyzed individually. Variables showing statistical significance, defined as 
p < 0.20 in univariate analyses were selected for the second stage, in which all variables 
were introduced in the multiple model. At this stage, variables showing p > 0.05 were 
removed from the model one by one, with “backward” selection of variables. Statistical 
significance of the prevalence ratios obtained in the Poisson regression models was 
assessed by the Wald test.
Data were stored in SPSS software for Windows version 18.0 (SPSS Inc., Chicago, IL, USA). 
Descriptive analyses were executed in SPSS and the Poisson regression models were 
executed in Stata software version 12.0 (Stata Corp LP, College Station, TX, USA), using 
the appropriate set of svy commands for the analysis of complex samples and ensuring the 
necessary weighting, considering the sample design.
The project was approved by the Brazilian National Commission for Research Ethics 
(CONEP – Opinion 398,131, September 16, 2013). Participants were only interviewed 
following permission by means of an informed consent signed by the researcher and 
the participant.
RESULTS
The children’s characteristics are shown in Table 1. The study population is comparable to 
that of the 2010 Census in relation to gender (50.9% boys and 49.1% girls), age (< 2 years: 
13.9%; 2-5 years: 29.0%; 6-12 years: 57.1%) and Brazilian region (North: 10.9%; Northeast: 
30.7%; Southeast: 37.9%; South: 12.9%; and Midwest: 6.7%)c.
The questionnaires were answered by the child’s mother in 76.1% of cases, followed by 
grandparent (9.6%) and father (8.6%).
Prevalence of chronic diseases was 9.9% (95%CI 8.6–11.3). Diabetes was reported by 0.4% of 
the sample (95%CI 0.2–0.8%) and chronic lung diseases by 5.2% (95%CI 4.3–6.4). Prevalence 
of acute conditions treated in the 15 days prior to the interview was 27.4% (95%CI 25.2–29.8). 
The most common were fever (8.4%; 95%CI 7.4–9.5), cold or flu (7.3%; 95%CI 6.2–8.5), pain 
(5.8%; 95%CI 4.8–7.0%) and infection (4.6%; 95%CI 3.8–5.5). The use of vitamins or mineral 
supplements was reported by 6.1% (95%CI 5.3–7.1).
Table 1 shows the prevalence of overall use of drugs and other products for therapeutic 
purposes (30.7%). Use was highest among children aged five or under, resident in the 
Northeast Region, with health insurance and who had used health services in the 
previous 12 months (one or more emergency visits and one or more hospitalizations). 
In the final model, these factors remained positively associated with the outcome, with 
statistical significance.
Table 2 shows the prevalence of drugs used to treat chronic (5.6%) and acute diseases 
(27.1%). Two years old or over, resident in the Southeast or South Regions, one or more 
emergency visits, and one or more hospitalizations remained positively associated 
with the use of medicines for chronic diseases. The positive association between health 
insurance and the outcome failed to show any statistical significance when adjusted 
for other variables.
The following factors were associated with the use of medicines to treat acute conditions 
in the crude analysis: five years old or younger, resident in the North, Northeast, and 
Midwest Regions, health insurance, and use of health services. In the multivariate 
analysis, these factors remained positively associated with the outcome and statistically 
significant, except for the number of hospitalizations. Belonging to economic classes 
A/B was negatively associated with the outcome, but not sustained after adjustment 
for covariates.
c Instituto Brasileiro de Geografia 
e Estatística. Censo demográfico 
2010: características da 
população e dos domicílios: 
resultado do universo. Rio de 
Janeiro (RJ): IBGE; 2011 [cited 
2016 Feb 29]. Available from: 
http://www.ibge.gov.br/home/
estatistica/populacao/censo2010/
caracteristicas_da_populacao/
default_caracteristicas_da_
populacao.shtm
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Table 1. Sample characteristics and overall prevalence of medicine use, according to demographic, socioeconomic and medical variablesa. 
(N = 7,528)
Variable
Sample Overall medicine use
% Prevalence 95%CI pb PRcrude 95%CI PRadjusted
c 95%CI
Overall 100 30.7 28.3–33.1 - - - - -
Gender 0.27 - - - -
Female 50.3 29.5 26.6–32.5 1 - 1 -
Male 49.7 31.9 28.6–35.3 1.08 0.94–1.24 1.08 0.94–1.24
Age (years) < 0.0001
< 2 13.5 48.0 44.8–51.2 2.01 1.77–2.29 1.78 1.58–2.00
2-5 26.9 37.1 34.4–39.9 1.56 1.36–1.78 1.33 1.17–1.52
6-12 59.6 23.8 20.9–27.0 1 1
Skin color 0.95
White 46.7 30.8 27.9–33.8 1 - 1 -
Non-white 53.3 30.9 28.0–33.9 1.00 0.90–1.12 1.00 0.90–1.12
Economic 
classificationd
0.2
A/B 16.8 27.0 22.9–31.4 1 - 1 -
C 56.2 31.5 28.7–34.5 1.17 0.99–1.38 1.17 0.99–1.38
D/E 27.0 31.1 27.3–35.2 1.15 0.96–1.39 1.09 0.91–1.31
Brazilian Region < 0.0001
North 9.9 32.5 25.5–40.3 1.24 0.94–1.63 1.22 0.97–1.53
Northeast 26.7 38.4 34.9–42.0 1.47 1.23–1.74 1.34 1.14–1.57
Southeast 41.2 26.9 22.8–31.5 1.03 0.83–1.28 0.99 0.81–1.20
South 13.8 26.2 22.5–30.2 1 - 1 -
Midwest 8.4 29.7 25.7–34.0 1.13 0.92–1.39 1.04 0.86–1.26
Health Insurance < 0.0001
Yes 19.3 37.9 33.0–43.0 1.31 1.13–1.51 1.28 1.11–1.47
No 80.7 28.9 26.5–31.05 1 - 1 -
No. of emergency 
visitse
< 0.0001
None 84.1 24.8 22.7–27.0 1 - 1 -
Two 9.5 51.5 44.3-58.7 2.08 1.76–2.45 1.79 1.52–2.11
Two or more 6.4 75.9 70.6-80.4 3.06 2.75–3.41 2.48 2.18–2.81
No. of 
hospitalizationse
< 0.0001
None 95.1 29.0 26.7-31.5 1 - 1 -
One 4.0 59.8 50.6-68.3 2.06 1.75–2.43 1.31 1.10–1.56
Two or more 0.9 85.4 74.6-92.1 2.94 2.58–3.34 1.37 1.19–1.58
a Percentages weighted by the sampling weights.
b Pearson’s Chi-Squared test.
c Poisson Regression.
d 2013 Brazilian Economic Classification according to ABEP.
e Regarding the 12 month-period prior to the interview.
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Table 2. Prevalence of medicine use for chronic diseases and acute conditions, according to demographic, socioeconomic and medical 
variablesa. (N = 7,528)
Variable
Medicine use for chronic diseases Medicine use for acute conditions
Prevalence 
(95%CI)
pb
PRcrude  
(95%CI)c
PRadjusted 
(95%CI)c
Prevalence 
(95%CI)
pb
PRcrude 
(95%CI)c
PRadjusted 
(95%CI)c
Overall 5.6 (4.7–6.7) 27.1 (24.8–29.4)
Gender 0.174 0.302
Female 4.9 (3.7–6.4) 1 1 26.1 (23.5–28.9) 1 1
Male 6.4 (4.9–8.3) 1.32 (0.88–1.98) 1.33 (0.91–1.94) 28.0 (25.0–31.3) 1.07 (0.94–1.23) 1.07 (0.94–1.23)
Age (years) 0.003 < 0.001
< 2 3.7 (2.8–4.8) 1 1 46.5 (43.3–49.7) 2.32 (2.02–2.67) 2.09 (1.83–2.38)
2-5 7.5 (6.0–9.3) 2.05 (1.51–2.80) 2.14 (1.56–2.94) 32.9 (30.0–35.8) 1.64 (1.43–1.89) 1.44 (1.25–1.66)
6-12 5.2 (4.1–6.7) 1.43 (1.02–2.01) 1.88 (1.35–2.61) 20.0 (17.4–22.9) 1 1
Skin color 0.104 0.779
White 6.4 (5.1–8.1) 1.30 (0.95–1.78) 1.10 (0.76–1.60) 27.0 (24.2–29.9) 0.98 (0.87–1.11) 0.98 (0.87–1.11)
Non-white 5.0 (3.9–6.3) 1 1 27.5 (24.7–30.4) 1
Economic 
classificationd
0.537 0.097
A/B 5.6 (3.7–8.4) 1.18 (0.68–2.06) 1.18 (0.68–2.06) 22.7 (18.9–27.0) 0.80 (0.65–0.98) 0.87 (0.70–1.08)
C 6.0 (4.8–7.5) 1.26 (0.81–1.97) 1.26 (0.81–1.97) 27.6 (24.6–30.6) 0.97 (0.83–1.13) 1.05 (0.91–1.20)
D/E 4.8 (3.3–6.9) 1 1 28.5 (24.8–32.5) 1 1
Brazilian Region < 0.001 < 0.001
North 2.6 (1.6–4.0) 1 1 31.0 (24.3–38.6) 1.53 (1.14–2.06) 1.52 (1.19–1.96)
Northeast 4.3 (3.1–6.0) 1.69 (0.97–2.97) 1.56 (0.92–2.63) 35.5 (32.2–39.0) 1.76 (1.43–2.17) 1.61 (1.33–1.95)
Southeast 6.8 (5.0–9.2) 2.66 (1.54–4.61) 2.93 (1.76–4.88) 22.8 (19.1–27.0) 1.13 (0.87–1.46) 1.10 (0.88–1.38)
South 7.7 (6.3–9.5) 3.02 (1.83–4.98) 3.56 (2.21–5.73) 20.2 (16.7–24.2) 1 1
Midwest 4.4 (2.6–6.0) 1.55 (0.83–2.87) 1.45 (0.83–2.53) 27.5 (23.5–32.0) 1.36 (1.07–1.73) 1.26 (1.01–1.57)
Health Insurance 0.021 0.007
Yes 8.4 (5.6–12.2) 1.68 (1.08–2.61) 1.28 (0.86–1.91) 32.2 (27.9–36.9) 1.25 (1.07–1.46) 1.26 (1.08–1.48)
No 5.0 (4.1–6.0) 1 1 25.8 (23.4–28.3) 1 1
No. of emergency 
visitse < 0.001 < 0.001
None 4.0 (3.3–5.0) 1 1 22.2 (20.1–24.3) 1 1
Two 7.5 (4.9–11.3) 1.86 (1.17–2.94) 1.55 (0.89–2.68) 45.2 (38.5–52.1) 2.04 (1.71–2.44) 1.80 (1.53–2.12)
Two or more 22.2 (16.2–29.7) 5.51 (3.82–7.93) 4.39 (2.62–7.34) 64.2 (58.0–70.1) 2.90 (2.56–3.27) 2.42 (2.12–2.78)
No. of hospitalizationse < 0.001 < 0.001
None 4.7 (3.8–5.7) 1 1 26.1 (23.9–28.5) 1 1
One 17.8 (11.3–26.9) 3.81 (2.30–6.28) 2.84 (1.50–5.38) 46.7 (38.0–55.7) 1.79 (1.45–2.20) 1.12 (0.92–1.36)
Two or more 44.3 (27.8–62.1)
9.46  
(6.13–14.61)
3.84 (2.29–6.43) 55.9 (37.8–72.6) 2.14 (1.54–2.97) 0.98 (0.70–1.37)
a Percentages weighted by the sampling weights.
b Pearson’s Chi-Squared test.
c Poisson Regression.
d 2013 Brazilian Economic Classification according to ABEP.
e Regarding the 12 month-period prior to the interview.
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Of the total number of products or drugs reported (5,185), 91.4% (95%CI 89.9–92.6) 
corresponded to medicines, 1.7% (95%CI 1.3–2.4) to dietary supplements (low-dose 
vitamin combinations), 1.2% (95%CI 0.9–1.7) to herbal medicines, 1.1% (95%CI 0.7–1.9) 
to plants or teas, 0.5% (95%CI 0.3–0.8) to food (honey compounds), and 0.1% (95%CI 
0.0–0.7) to homeopathic medicines. The name of 3.9% (95%CI 3.0–5.1) of the products 
was not identified.
Table 3 shows the prevalence of medicines most used by Brazilian children (equal to or 
above 0.5%). Considering the total sample, the highest prevalence in drug use was observed 
for dipyrone (5.1%; 95%CI 4.3–6.1), paracetamol (4.3%; 95%CI 3.6–5.1), and amoxicillin (2.7, 
95%CI 2.2–3.4).
Tables 4 and 5 show, for each age group, the drugs reported in treating chronic and acute 
diseases, respectively. Prominent among the total number of drugs to treat chronic diseases 
were those acting on the respiratory system (salbutamol, dexchlorpheniramine, fluticasone, 
and phenoterol), in all age groups (Table 4). Painkillers were the most cited drugs for treating 
acute conditions (Table 5).
Table 3. Prevalence of most often used medicines (prevalence of use ≥ 0.5%) by children, by age 
groupa. (N = 7,528)
Drugb
< 2 years  
(n = 2,302)
2-5 years  
(n = 3,671)
6-12 years  
(n = 1,555)
Total  
(n = 7,528)
Prevalence 95%CI Prevalence 95%CI Prevalence 95%CI Prevalence 95%CI
Dypirone 5.7 4.5–7.2 6.2 4.9–7.7 4.6 3.4–6.1 5.1 4.3–6.1
Paracetamol 10.1 8.6–11.8 5.9 4.6–7.5 2.2 1.5–3.2 4.3 3.6–5.1
Amoxicilin 3.4 2.6–4.6 4.0 3.2–5.0 2.0 1.3–3.1 2.7 2.2–3.4
Ibuprofen 3.9 3.0–5.0 3.3 2.5–4.5 1.7 1.0–2.8 2.4 1.9–3.1
Ascorbic acid 6.9 5.5–8.6 1.9 1.3–2.9 0.3 0.1–0.7 1.6 1.3–2.0
Dexchlorpheniramine 1.5 1.0–2.2 1.7 1.2–2.4 1.6 0.9–2.5 1.6 1.2–2.2
Ambroxol 1.3 0.8–2.0 1.3 0.8–2.3 0.8 0.4–1.4 1.0 0.7–1.4
Prednisolone 1.7 1.1–2.8 1.6 1.2–2.2 0.6 0.3–1.3 1.0 0.7–1.4
Ferrous sulphate 4.0 3.0–5.5 0.4 0.2–0.7 0.4 0.1–1.1 0.9 0.6–1.3
Cholecalciferol; retinol 5.7 3.9–8.3 0.2 0.1–0.6 0 0.0–0.0 0.8 0.6–1.2
Multivitamins 4.0 3.0–5.3 0.4 0.2–0.6 0.1 0.0–0.3 0.7 0.5–0.9
Dimethicone 3.7 2.8–5.1 0.6 0.2–1.8 0.1 0.0–0.6 0.7 0.5–1.1
Loratadine 0.6 0.3–1.1 0.9 0.6–1.4 0.6 0.3–1.2 0.6 0.4–1.0
Fluticasone 0 0.0–0.3 0.7 0.2–1.8 0.7 0.3–2.0 0.6 0.2–1.6
Sulfamethoxazol; 
trimethropim
0.9 0.6–1.4 1.0 0.7–1.5 0.2 0.0–0.6 0.5 0.3–0.7
Salbutamol 0.7 0.4–1.4 0.9 0.6–1.3 0.3 0.1–0.9 0.5 0.3–0.8
Nimesulide 0.4 0.2–0.8 0.5 0.3–0.9 0.5 0.2–1.0 0.5 0.3–0.8
Cephalexin 0.9 0.6–1.5 0.8 0.4–1.5 0.2 0.1–0.7 0.5 0.3–0.8
Amoxicilin; potassium 
clavulanate
0.4 0.2–1.1 0.9 0.4–2.0 0.2 0.1–1.0 0.5 0.2–0.9
Phenoterol 0.4 0.2–1.0 0.7 0.3–1.4 0.4 0.2–1.1 0.5 0.3–0.9
a Percentages weighted by the sampling weights. 
b Excluding supplements, food, plants and herbal medicines.
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Table 4. Most used medicines (frequency > 1.0%) for chronic diseases, by age groupa.
< 2 years Preschool age (2-5 years) School age (6-12 years)
(n = 119 
medicines)
% 95%CI
(n = 295 
medicines)
% 95%CI
(n = 115 
medicines)
% 95%CI
Salbutamol 8.4 3.5–18.7 Salbutamol 5.8 3.4–9.9 Carbamazepine 9.1 3.8–20.4
Prednisolone 7.2 3.0–15.9 Phenoterol 5.3 2.6–10.6 Fluticasone 9.1 2.8–26.0
Dexchlorpheniramine 7.0 3.0–15.4 Fluticasone 5.0 1.7–13.4 Dexchlorpheniramine 5.6 2.0–15.0
Amoxicilin 6.6 2.7–15.4 Prednisolone 4.5 2.5–8.1 Phenoterol 4.9 1.8–12.4
Beclomethasone 5.5 1.5–18.0 Ipratropium 4.2 1.7–9.7 Salbutamol 4.7 2.0–10.7
Ferrous sulphate 4.1 1.2–13.0 Phenobarbital 4.0 1.5–9.9
Budesonide; 
formoterol
4.6 1.4–14.0
Phenobarbital 3.7 1.5–8.9 Sodium chloride 3.7 0.9–13.9 Ipratropium 3.5 0.9–12.5
Bethametasone; 
Dexchlorpheniramine
3.2 1.1–9.0 Beclomethasone 3.6 1.7–7.4 Levothyiroxine 3.1 0.7–12.8
Loratadine 3.1 0.7–12.7 Risperidone 3.4 0.7–14.4 Methylphenidate 3.0 0.6–12.8
Sodium chloride 2.6 0.9–7.9 Desloratadine 3.4 0.7–14.3 Loratadine 3.0 0.8–10.4
Prednisone 2.6 0.3–17.4 Ketotifen 2.9 0.9–9.3 Budesonide 3.0 1.0–8.2
Bronpheniramine; 
Phenylephrine
2.5 0.5–11.9 Ascorbic acid 2.9 0.4–17.4 Prednisolone 2.9 1.0–7.8
Multivitamins 2.4 0.3–16.0 Vitamins B Complexb 2.9 0.4–17.4 Tacrolimus 2.5 0.5–12.9
Dexamethasone 2.3 0.7–7.6 Pericyazine 2.9 0.5–15.5 Human insulin 2.5 0.3–16.6
Domperidone 2.2 0.7–6.8 Dexchlorpheniramine 2.3 1.1–5.0
Methlylprednisolon 
acetate
2.3 0.3–13.5
Ketotifen 2.2 0.3–14.1 Carbamazepine 2.2 0.6–7.2 Divalproex sodium 2.1 0.3–14.0
Cromoglycate 2.2 0.3–13.0 Budesonide 2.1 0.9–4.6 Oxcarbazepine 2.1 0.3–13.5
Acebrophylline 2.1 0.7–6.0 Montelukast 2.0 0.8–4.9 Topiramate 2.1 0.3–13.5
Ambroxol 1.9 0.4–9.3
Betamethasone; 
Dexchlorpheniramine
2.0 0.6–5.9 Folic acid 1.7 0.4–7.8
Folic acid 1.9 0.3–12.9 Amoxicilin 1.9 0.8–4.3 Olopatadine 1.5 0.2–10.9
Ibuprofen 1.8 0.6–4.9 Dihidroxizine 1.8 0.3–10.4 Phenobarbital 1.4 0.2–7.8
Thiabendazol 1.6 0.2–11.3 Loratadine 1.7 0.6–4.4 Calcitriol 1.2 0.2–8.7
Phenoterol 1.5 0.2–10.6
Clobutinol; 
doxylamine
1.7 0.2–10.8 Biperiden 1.2 0.2–8.3
Desloratadine 1.3 0.3–6.1
Calcium; 
nicotinamide; 
panthenol; abscorbic 
acid
1.6 0.2–10.9 Chlorpromazine 1.2 0.2–8.3
Amoxicilin; 
potassium 
Clavulanate
1.3 0.2–9.1 Ibuprofen 1.4 0.5–4.2 Dimethicone 1.2 0.2–8.3
Ferripolimaltose 1.2 0.2–6.1 Acebrophylline 1.4 0.5–3.9
Dipyrona; 
scopolamine
1.2 0.2–8.3
Beclomethasone; 
salbutamol
1.1 0.1–7.5 Mometasone 1.3 0.5–3.4 Haloperidol 1.2 0.2–8.3
Budesonide 1.1 0.2–6.8 Omeprazole 1.2 0.2–8.3
Cholecalciferol; 
retinol
1.1 0.2–6.8 Sodium picosulfate 1.2 0.2–8.7
Ranitidine 1.1 0.2–6.8
a Excluding herbal medicines and other products for therapeutic purpose reported by respondents (dietary 
supplements, food, plants and homeopathic products).
b Biotin, cyanocobalamin, pyridoxine, thiamine, riboflavin, nicotinamide, panthenol and calcium pantothenate.
9s
Use of medicines among children in Brazil da Silva Dal Pizzol T et al.
DOI:10.1590/S1518-8787.2016050006115
DISCUSSION
This is the first study of drug use in children with a representative sample of the Brazilian 
urban population, providing estimates of the prevalence of drug use based on the chronic 
or acute nature of the treated health problem. The profile of medicine users and the most 
frequently used pharmacological agents in each phase of childhood are also described in 
this study.
Prevalence of overall drug use was lower than that observed in studies involving drug use in 
the previous seven days by children under 12 living in the US (56.0%)25 and individuals aged 
zero to 17 in Germany (50.8%)15. However, it was similar to that observed in surveys based 
on two-week periods in Spain4 and Norway10. In Spain, surveys with children aged zero to 
15 carried out in 1993 and 2003 showed prevalence rates of 36.8% and 34.0%, respectively4. 
In Norway, about 25.0% of children up to four years of age used medicines, decreasing to 
approximately 20.0% among older children10. Compared to studies carried out in Brazil, 
prevalence was lower than that observed in Salvador, BA23, Bagé, RS19, and the Jequitinhonha 
Valley, MG8.
The significant difference between prevalence of drug use to treat chronic diseases and 
acute conditions was expected, considering that this population group is characterized by 
predominantly healthy individuals. Although Cox et al.7 (2008) observed an increase in the 
prevalence of certain chronic diseases among American children aged five to 19, children 
are most commonly affected by acute medical conditions, directly influencing how drugs 
are used (continuous versus occasional use).
The lack of difference in prevalence of overall drug use or related to acute events between 
boys and girls is in accordance with recent studies4,8,19. The decrease in the prevalence of 
overall drug use or related to acute conditions as age increases corroborates findings from 
studies that showed increased use among children under two years old, compared to older 
Table 5. Most used medicines (frequency > 1.0%) for acute conditions, by age groupa.
< 2 years Preschool age (2-5 years) School age (6-12 years)
(n = 1,829 medicines) % 95%CI (n = 1,868 medicines) % 95%CI (n = 385 medicines) % 95%CI
Paracetamol 13.1 11.4–15.1 Dipirone 13.3 10.7–16.3 Dipirone 18.5 14.3–23.6
Ascorbic acid 8.9 7.1–11.0 Paracetamol 12.8 10.3–15.8 Paracetamol 9.1 6.2–13.0
Dipyrone 7.3 5.9–9.1 Amoxicilin 8.3 6.7–10.3 Amoxicilin 8.0 5.2–12.0
Cholecalciferol; retinol 7.1 4.9–10.1 Ibuprofen 6.9 5.2–9.2 Ibuprofen 7.1 4.5–11.2
Ibuprofen 5.0 3.9–6.4 Ascorbic acid 3.4 2.5–4.6 Dexchlorpheniramine 4.8 2.9–7.9
Multivitaminas 5.0 3.7–6.6 Dexchlorpheniramine 3.2 2.2–4.5 Ambroxol 3.1 1.7–5.6
Ferrous sulphate 4.9 3.6–6.7 Ambroxol 2.8 1.6–4.8 Nimesulide 2.0 1.0–4.1
Dimethicone 4.8 3.6–6.4 Prednisolone 2.4 1.7–3.5 Mebendazole 1.7 0.6–4.5
Amoxicilin 4.1 3.1–5.5
Sulfamethoxazole; 
trimethoprim
2.1 1.4–3.3 Prednisolone 1.6 0.5–4.5
Ferripolimaltose 2.0 1.3–3.2
Amoxicilin; potassium 
clavulanate
1.8 0.8–4.2 Ferrous sulphate 1.6 0.5–4.6
Bronpheniramine; phenylephrine 1.9 1.2–3.0 Cephalexine 1.6 0.8–3.0 Albendazole 1.4 0.4–4.6
Prednisolone 1.8 1.1–2.9 Azitromycin 1.5 0.5–4.0 Fexofenadine 1.3 0.4–4.6
Ambroxol 1.5 1.0–2.4 Loratadine 1.4 0.9–2.3 Loratadine 1.3 0.5–3.0
Dexchlorpheniramine 1.5 1.0–2.2 Dimethicone 1.3 0.4–3.9 Azithromycin 1.1 0.3–3.8
Soidum chloride 1.2 0.7–2.2 Bromopride 1.3 0.5–3.2
Sulfamethoxazole; trimethoprim 1.2 0.8–1.8 Nimesulide 1.1 0.7–1.8
Cephalexina 1.1 0.6–1.9 Vitamins B complexb 1.1 0.4–2.7
Betamethasone; 
dexchlorpheniramine
1.1 0.6-2.0
a Excluding herbal medicines and other products for therapeutic purpose reported by respondents (dietary supplements, food, plants and homeopathic products).
b Cyproheptadine, ascorbic acid, propylene glycol, thiamine, pyridoxine, nicotinamide and riboflavin.
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children4,12,15,16. These findings indicate that the first 24 months of life, when children are 
more susceptible to diseases and receive more medical care, either elective or emergency, are 
followed by a period of low incidence of acute conditions, which lasts approximately until 
early adolescence. Menarche-related events entail the use of painkillers and contraceptives 
by adolescent girls, contributing to increased prevalence in this age group2.
The data of this study show that the profile of drug use to treat acute or chronic health 
conditions differs according to region. The highest prevalence of use for chronic 
conditions was observed in the South and Southeast Regions, associated with the 
higher prevalence of chronic respiratory diseases in these regions (data not shown). The 
use of drugs for acute conditions, higher in the Northeast and North Regions, can be 
explained by the higher frequency of medicine use for diarrhea and other gastrointestinal 
disorders, and the higher percentage of self-medication in these regions, according to 
PNAUM data not shown.
An overall positive association was found between use of health services and use of medicines, 
in line with data from the 2003 Spanish survey4. Contact with health care services provides 
greater chances of children receiving medical prescriptions, which may lead to the routine 
use of prescription drugs or new posterior use.
Medicines to control pain and fever are among the most used, according to previous 
studies4,8,19,25. Dipyrone is the most used analgesic and antipyretic, followed by paracetamol 
and ibuprofen. This pattern differs from that observed in studies carried out in countries 
where the use of dipyrone has been banned or restricted, as in the US, where ibuprofen 
stands out as the second most used painkiller25. Amoxicillin was the most used antimicrobial 
in all age groups, with higher prevalence among children aged two to five (4.0%) and lower 
prevalence among children aged six to 12 (2.0%). In the US, amoxicillin also ranked as the 
most widely used antimicrobial, with higher prevalence among children under two years 
of age (5.1%) and lower prevalence in the six to 11 age group (1.5%)25. With the exception of 
dipyrone, whose safety controversies have persisted for years, the other drugs mentioned 
are considered effective and safe, with good evidence for pediatric use21.
Another fact that draws attention relates to the use of vitamins, alone or in combination. 
The use of ascorbic acid alone was superior to the use of multivitamins in all age groups 
investigated, in contrast to the findings of a US study, in which multivitamins were mentioned 
more often25 (2009). In Salvador, vitamin C was used more often than multivitamins, although 
the difference observed in prevalence of use was smaller24.
Prominent among the 10 most mentioned drugs for use in chronic diseases are those 
indicated for respiratory diseases such as asthma and rhinitis, followed by those with 
therapeutic use in epilepsy. Among children below two years old it is observed use of various 
drugs without FDA approval for this age group and no indication in the standard package 
inserts approved by ANVISAd. Among the most frequently cited drugs with restrictions 
for use in this age group are salbutamol, dexchlorpheniramine (alone or combined with 
betamethasone), loratadine, and brompheniramine + phenylephrine. It should be noted 
that, in some cases, drugs not approved by the FDA are indicated in Brazilian standard 
package inserts, as is the case of betamethasone and ambroxold,e. If, on the one hand, the use 
of non-approved drugs may represent a potentially inappropriate administration of drugs 
whose efficacy and safety have not been established, on the other it may reflect the lack of 
therapeutic options to treat health conditions prevalent in children, such as asthma, rhinitis, 
and acute or chronic coughing, among others5.
Among children under two years of age, one of the most used drugs to treat chronic 
diseases was amoxicillin. This can be explained by recurrent respiratory infections in this 
age group, identified as chronic by parents or caregivers for occurring with high frequency 
in short periods of time. This finding should be considered in the context of the increase in 
antimicrobial resistance rates reported worldwide and in Brazil11,22.
d Ministério da Saúde, Agência 
Nacional de Vigilância Sanitária. 
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Regarding medicines most used in acute conditions, important differences are found 
in the characteristics of the most commonly used drugs in the first two years of life 
compared to older children. The presence of ascorbic acid, cholecalciferol+retinol, ferrous 
sulfate and multivitamins among the 10 drugs most used by children under 12 shows 
that supplementation with vitamins alone or in combination in the first years of life is 
common practice in pediatrics, despite not always being supported by evidence9,14,26. Among 
preschool children, what draws attention is the higher frequency of antimicrobials, including 
amoxicillin, sulfamethoxazole+trimethropim, and amoxicillin+clavulanate, among the 
10 most cited drugs. These results suggest that with increasing age, the higher incidence of 
infectious diseases, particularly respiratory, leads to greater use of antimicrobials. The age 
groups of two to five years and six to 12 years show the use of nimesulide, a drug with risk 
of liver toxicity and Reye’s syndrome in children with symptoms of viral infection, being 
contraindicated for children under the age of 12 according to the standard package insert 
approved by ANVISA.
This study has limitations. It uses information provided by interviewees on the presence of 
chronic disease, which can lead to overestimation of prevalence of use. On the other hand, 
socio-cultural aspects involving the use of medicines, particularly when related to risk 
groups, may contribute to parents (the main respondents in this research) giving socially 
desirable answers4,25. Thus, omissions in reporting the use of certain medicines cannot be 
ruled out. Finally, the use of drugs for diseases that are typical in colder months, especially 
in the South and Southeast Regions, may be underrepresented, given that data collection 
occurred during spring and summer.
The results of this study indicate that a considerable percentage of Brazilian children 
make use of medicines, especially to treat acute conditions. Children using drugs for 
chronic diseases have a different demographic profile compared to those using drugs 
for acute conditions according to gender, age, and geographic region. Among the most 
commonly used drugs are medicines acknowledged as effective for pediatric use and 
others whose effectiveness and safety are uncertain when used in children, particularly 
those under the age of two.
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